公开(公告)号：US11667688B2

公开(公告)日：2023-06-06

申请号：US17576519

申请日：2022-01-14

申请人： HANMI PHARM. CO., LTD.

发明人： Jung Kuk Kim ,  Young Jin Park ,  In Young Choi ,  Sung Youb Jung

IPC分类号： A61K38/26 ,  A61K38/28 ,  C07K14/605 ,  A61K38/22 ,  A61K47/60 ,  A61K47/68 ,  A61P3/08 ,  A61P3/00 ,  A61P3/04

CPC分类号： C07K14/605 ,  A61K38/2264 ,  A61K38/2278 ,  A61K38/26 ,  A61K38/28 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6811 ,  A61P3/00 ,  A61P3/04 ,  A61P3/08 ,  A61K38/26 ,  A61K2300/00 ,  A61K38/28 ,  A61K2300/00 ,  A61K38/2264 ,  A61K2300/00 ,  A61K38/2278 ,  A61K2300/00

摘要： A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

公开(公告)号：US11254724B2

公开(公告)日：2022-02-22

申请号：US16684110

申请日：2019-11-14

申请人： HANMI PHARM CO., LTD.

发明人： Sung Youb Jung ,  Young Jin Park ,  Jong Suk Lee ,  Jae Hyuk Choi ,  Chang Ki Lim ,  Se Chang Kwon

IPC分类号： C07K14/605 ,  A61K38/26 ,  A61K45/06 ,  A61K38/00

摘要： The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity.

公开(公告)号：US11142559B2

公开(公告)日：2021-10-12

申请号：US16233890

申请日：2018-12-27

申请人： HANMI PHARM. CO., LTD

发明人： Jung Kuk Kim ,  Young Jin Park ,  In Young Choi ,  Sung Youb Jung

IPC分类号： A61K38/26 ,  C07K14/605 ,  A61K45/06 ,  A61K38/28 ,  A61K47/50 ,  A61K38/17 ,  A61K47/68 ,  A61K47/60 ,  A61P3/08 ,  A61P3/04

摘要： The present invention relates to a glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof, and in particular, for metabolic syndrome, hypoglycemia, and congenital hyperinsulinism.

公开(公告)号：US10188703B2

公开(公告)日：2019-01-29

申请号：US15315020

申请日：2015-06-01

申请人： HANMI PHARM. CO., LTD.

发明人： Sung Youb Jung ,  Sang Youn Hwang ,  Seung Su Kim ,  In Young Choi ,  Se Chang Kwon

IPC分类号： A61K38/28 ,  A61K38/26 ,  C07K16/46 ,  C07K19/00 ,  A61K47/68 ,  A61K47/60 ,  A61K47/50

摘要： A composition for preventing or treating diabetes mellitus includes insulin and a GLP-1/glucagon dual agonist. The composition can inhibit the weight gain and reduce the danger of hypoglycemia due to the administration of insulin, lower the administration dose and greatly improve the compliance of drugs through a combined administration of a long-acting insulin conjugate and a long-acting GLP-1/glucagon dual agonist conjugate. In addition, the long-acting insulin conjugate and the long-acting GLP-1/glucagon dual agonist conjugate can improve the in vivo sustainability and stability because an insulin and a GLP-1/glucagon dual agonist are linked to the immunoglobulin Fc region via a non-peptidyl linker. A method for preventing or treat diabetes mellitus includes administration of the insulin and a GLP-1/glucagon dual agonist.

公开(公告)号：US10159715B2

公开(公告)日：2018-12-25

申请号：US15313501

申请日：2015-05-29

申请人： HANMI PHARM. CO., LTD.

发明人： Jung Kuk Kim ,  Dae Jin Kim ,  Yong Ho Heo ,  In Young Choi ,  Sung Youb Jung ,  Se Chang Kwon

IPC分类号： A61K38/26 ,  A61K38/28 ,  A61K47/30 ,  C07K16/28 ,  A61K47/60 ,  A61K47/50 ,  A61K47/68

摘要： The present invention relates to a composition for the prevention or treatment of diabetes including a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a method for treating diabetes. More specifically, combination administration of the long-acting analog conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain due to administration of insulin, and vomiting and nausea due to administration of the insulinotropic peptide, and also reduces the required doses of insulin, thereby remarkably improving drug compliance. In addition, the present invention relates to administering a pharmaceutical composition for reducing side effects of pancreatic beta cells in diabetic patients, including a long-acting insulin analog conjugate and a long-acting insulinotropic peptide analog conjugate, and to a method for reducing side effects of pancreatic beta cells in diabetic patients, including the step of administering the composition. Specifically, the present invention is characterized in reducing side effects such as abnormality in the function of pancreatic beta cells associated with the development of diabetes, reduction in the pancreatic beta cell mass, lipotoxicity, or glucotoxicity.

公开(公告)号：US11752216B2

公开(公告)日：2023-09-12

申请号：US16495884

申请日：2018-03-23

申请人： HANMI PHARM. CO., LTD.

发明人： Young Jin Park ,  In Young Choi ,  Sung Youb Jung ,  Se Chang Kwon

IPC分类号： C07K14/62 ,  A61K47/68 ,  A61K47/60 ,  A61P3/10 ,  A61K38/00

CPC分类号： A61K47/6883 ,  A61K47/60 ,  A61P3/10 ,  C07K14/62 ,  A61K38/00

摘要： The present invention relates to an insulin analog conjugate and use thereof.

公开(公告)号：US11332508B2

公开(公告)日：2022-05-17

申请号：US16370057

申请日：2019-03-29

申请人： HANMI PHARM. CO., LTD

发明人： Euh Lim Oh ,  Jong Suk Lee ,  Young Jin Park ,  Chang Ki Lim ,  Sung Youb Jung ,  Se Chang Kwon

IPC分类号： A61K38/00 ,  C07K14/605 ,  A61K38/26 ,  A61P3/04 ,  A61P3/10 ,  A61K39/395 ,  C07K14/47 ,  C07K16/28 ,  A61K47/60 ,  A61P9/10 ,  A61P9/12

摘要： A a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors is disclosed. Uses of the triple agonist are disclosed.

公开(公告)号：US10435459B2

公开(公告)日：2019-10-08

申请号：US16267880

申请日：2019-02-05

申请人： HANMI PHARM. CO., LTD.

发明人： Sang Youn Hwang ,  Jin Young Kim ,  Seung Su Kim ,  In Young Choi ,  Sung Youb Jung ,  Se Chang Kwon

IPC分类号： A61K38/00 ,  C07K16/00 ,  A61K38/26 ,  A61K47/60 ,  A61K47/68 ,  A61K49/00

摘要： The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting GLP-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side effect of weight gain, which is a side-effect of conventional therapeutic agents for non-alcoholic fatty liver disease, and reduces the amount of administrations of a long-acting GLP-1/glucagon receptor dual agonist, thus greatly improving patient's convenience. In addition, the long-acting GLP-1/glucagon receptor dual agonist of the present invention improves in vivo sustainability and stability.

公开(公告)号：US10400020B2

公开(公告)日：2019-09-03

申请号：US16024014

申请日：2018-06-29

申请人： HANMI PHARM. CO., LTD.

发明人： Euh Lim Oh ,  Jong Suk Lee ,  Young Jin Park ,  Chang Ki Lim ,  Sung Youb Jung ,  Se Chang Kwon

IPC分类号： A61K38/00 ,  C07K14/605 ,  A61K38/26 ,  A61K39/395 ,  A61P3/04 ,  A61P3/10 ,  C07K16/28 ,  C07K14/47 ,  A61P9/12 ,  A61K47/60 ,  A61P9/10

摘要： The present invention relates to a long-acting conjugate of a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.

公开(公告)号：US10253082B2

公开(公告)日：2019-04-09

申请号：US15113027

申请日：2015-01-20

申请人： HANMI PHARM. CO., LTD.

发明人： Sung Youb Jung ,  Sang Youn Hwang ,  Euh Lim Oh ,  Sung Hee Park ,  Hyun Uk Kim ,  Chang Ki Lim ,  Se Chang Kwon

IPC分类号： A61K38/28 ,  C07K14/62 ,  A61K38/00

摘要： The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.